The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.

Pacesa argues that closed-source models won't significantly outperform open-source tools because most rely on the same public PDB data. The true competitive advantage lies not in tweaking algorithms but in generating massive, proprietary, high-quality experimental datasets that can train genuinely superior models.

The bottleneck for AI in drug discovery is not the algorithm but the lack of high-quality, large-scale biological data. New platforms are needed to generate this necessary "substrate" for AI models to learn from, challenging the narrative that better models alone are the solution.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

The future of valuable AI lies not in models trained on the abundant public internet, but in those built on scarce, proprietary data. For fields like robotics and biology, this data doesn't exist to be scraped; it must be actively created, making the data generation process itself the key competitive moat.

As AI models become commoditized, the ultimate defensibility comes from exclusive access to a unique dataset. A startup with a slightly inferior model but a comprehensive, proprietary dataset (e.g., all legal records) will beat a superior, general-purpose model for specialized tasks, creating a powerful long-term advantage.

The vague concept of a 'data network effect' is now a real defensibility strategy in AI. The key is having a *live*, constantly updating proprietary dataset (e.g., real-time health data). This allows a commodity model to deliver superior results compared to a state-of-the-art model without access to that live data.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.